Colchicine, Drugs Monitor

(18 May 2021) Colchicine- not associated with reductions in 28-day mortality

May 27, 2021

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial https://www.medrxiv.org/content/10.1101/2021.05.18.21257267v1 NCT04381936-Between 27 November 2020 and 4 March 2021, 5610 patients were randomly allocated to receive colchicine and 5730 patients to receive usual care alone.… Continue reading "(18 May 2021) Colchicine- not associated with reductions in 28-day mortality"

(25 Mar 2021) Colchicine- associated with reduced mortality and accelerated recovery in COVID-19 patients

April 7, 2021

Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study https://doi.org/10.1371/journal.pone.0248276 Amongst the 141 COVID-19 patients (118 [83.7%] hospitalized), 70 (50%) received colchicine. The 21-day crude cumulative mortality was 7.5% in the colchicine group and 28.5%… Continue reading "(25 Mar 2021) Colchicine- associated with reduced mortality and accelerated recovery in COVID-19 patients"

(19 Mar 2021) Colchicine- 1 mg for 1-3 days followed by 0.5 mg/day for 14 days effective as a proactive anti-inflammatory

April 7, 2021

Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study https://doi.org/10.18087/cardio.2021.2.n1560 In the control group, the CRP levels decreased moderately and statistically insignificantly and achieved 22.8 mg/dL by… Continue reading "(19 Mar 2021) Colchicine- 1 mg for 1-3 days followed by 0.5 mg/day for 14 days effective as a proactive anti-inflammatory"

(06 Feb 2021) Colchicine-reduced the length of both, supplemental oxygen therapy and hospitalisation

February 16, 2021

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial https://doi.org/10.1136/rmdopen-2020-001455 Trial number: RBR-8jyhxh- Seventy-two patients (36 for placebo and 36 for colchicine) completed the study. Median (and IQR) time of need for supplemental oxygen… Continue reading "(06 Feb 2021) Colchicine-reduced the length of both, supplemental oxygen therapy and hospitalisation"

(27 Jan 2021) Colchicine- reduces the composite rate of death or hospitalization

January 28, 2021

Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1 NCT04322682- A total of 4488 patients were enrolled. The primary endpoint occurred in 4.7% of the patients in the colchicine group and 5.8% of those in the placebo group (odds ratio,… Continue reading "(27 Jan 2021) Colchicine- reduces the composite rate of death or hospitalization"

Tag: Colchicine

(18 May 2021) Colchicine- not associated with reductions in 28-day mortality

(25 Mar 2021) Colchicine- associated with reduced mortality and accelerated recovery in COVID-19 patients

(19 Mar 2021) Colchicine- 1 mg for 1-3 days followed by 0.5 mg/day for 14 days effective as a proactive anti-inflammatory

(06 Feb 2021) Colchicine-reduced the length of both, supplemental oxygen therapy and hospitalisation

(27 Jan 2021) Colchicine- reduces the composite rate of death or hospitalization